Sonoma Biotherapeutics News and Activities

View the org chart displaying its 27 main executives

Most searched biographies at Sonoma Biotherapeutics

• Stephen Dilly, President and Chief Executive Officer
• Rick Klausner, Chairman of the Board
• Jeffrey Bluestone, Director

Popular executive movements at Sonoma Biotherapeutics

• Stephen Dilly has joined the company as President and Chief Executive Officer  (posted on November 18 2025).
• Jeffrey Bluestone who was Chief Executive Officer, President and Director, becomes Director  (posted on November 18 2025).

Create your alert
to follow the executive moves at Sonoma Biotherapeutics.

Sonoma Biotherapeutics has 2,413 competitors including Lonza (Switzerland), Eurofins (Luxembourg) and Vertex Pharmaceuticals (United States (USA)).

Popular M&A news in Biotechnology

• Memento Medicines has just announced a $93 Million fundraising (posted on June 22 2026).
• Alvotech has just announced a $165 Million fundraising (posted on June 19 2026).
• Obsidian Therapeutics has filed its IPO. Its stock ticker will be OBX. (posted on June 18 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Carl Gordon - Director at Odyssey Therapeutics
• Jan Van de Winkel - President and Chief Executive Officer at Genmab

Learn more about the Biotechnology industry

Press releases by Sonoma Biotherapeutics

• SF researcher among 3 scientists awarded Nobel Prize in medicine for work on the human immune system
• News | Sonoma Biotherapeutics
• News | Sonoma Biotherapeutics
• Sonoma Biotherapeutics to Present Preclinical Data from Novel Treg Cell Therapy for Rheumatoid Arthritis at American College of Rheumatology Convergence 2022
• Sonoma Bio to cement its roots in Seattle with a new waterfront manufacturing and R&D site
• Sonoma Biotherapeutics Appoints Jessica Stitt as Chief Financial Officer
• Sonoma Biotherapeutics Enters Long-Term Lease Agreement to Establish a Treg Cell Therapy R&D and Manufacturing Center
• Sonoma Biotherapeutics Expands Board of Directors with Appointments of Katina Dorton, J.D., MBA, and John Davis, M.D., MPH
• Sonoma Biotherapeutics Announces FDA Clearance of Investigational New Drug Application for SBT115301, an Effector T Cell-Modulating Biologic for Autoimmune Diseases
• View more press releases Close

Social media about Sonoma Biotherapeutics

• Sonoma Biotherapeutics on Wikipedia, Google News & Yahoo Finance
• Sonoma Biotherapeutics on LinkedIn, X (Twitter) & YouTube